PIK3CD and neoplasm: Based on the continuous crosstalk between immune and metabolic signals in TME and the effect of metabolic pathways in immune cells, integrating immunometabolic signaling pathways with phosphatidylinositol-3 kinase (PI3K)-protein kinase B (AKT/PKB), mechanistic target of rapamycin (mTOR) and liver kinase B1–5′ AMP-activated protein kinase (LKB1-AMPK) as the central link between immune signaling and metabolic pathways considerably influences tumor progression.